Polypid Stock Current Asset
| PYPD Stock | USD 3.46 0.05 1.42% |
PolyPid fundamentals help investors to digest information that contributes to PolyPid's financial success or failures. It also enables traders to predict the movement of PolyPid Stock. The fundamental analysis module provides a way to measure PolyPid's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PolyPid stock.
The current year's Other Current Assets is expected to grow to about 878.4 K, whereas Non Current Assets Total are forecasted to decline to about 7.8 M. PolyPid | Current Asset |
PolyPid Company Current Asset Analysis
PolyPid's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
PolyPid Current Asset Historical Pattern
Today, most investors in PolyPid Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PolyPid's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of PolyPid current asset as a starting point in their analysis.
PolyPid Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
PolyPid Total Assets
Total Assets |
|
In accordance with the recently published financial statements, PolyPid has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
PolyPid ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PolyPid's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PolyPid's managers, analysts, and investors.Environmental | Governance | Social |
PolyPid Fundamentals
| Return On Equity | -4.97 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 23.21 M | ||||
| Shares Outstanding | 6.8 M | ||||
| Shares Owned By Insiders | 24.24 % | ||||
| Shares Owned By Institutions | 36.74 % | ||||
| Number Of Shares Shorted | 13.01 K | ||||
| Price To Book | 10.53 X | ||||
| EBITDA | (20.26 M) | ||||
| Net Income | (23.86 M) | ||||
| Cash And Equivalents | 23.78 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 11.78 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 2.87 X | ||||
| Book Value Per Share | (1.27) X | ||||
| Cash Flow From Operations | (17.24 M) | ||||
| Short Ratio | 2.29 X | ||||
| Earnings Per Share | (7.22) X | ||||
| Target Price | 11.75 | ||||
| Number Of Employees | 59 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 23.51 M | ||||
| Total Asset | 15.37 M | ||||
| Retained Earnings | (238.31 M) | ||||
| Working Capital | (1.22 M) | ||||
| Net Asset | 15.37 M |
About PolyPid Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PolyPid's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPid using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPid based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PolyPid is a strong investment it is important to analyze PolyPid's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PolyPid's future performance. For an informed investment choice regarding PolyPid Stock, refer to the following important reports:Check out PolyPid Piotroski F Score and PolyPid Altman Z Score analysis. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PolyPid. If investors know PolyPid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PolyPid listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.22) | Return On Assets (0.65) | Return On Equity (4.97) |
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PolyPid's value and its price as these two are different measures arrived at by different means. Investors typically determine if PolyPid is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PolyPid's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.